Risk Stratified Sequential Treatment for CD20-positive PTLD

NCT ID: NCT00590447

Last Updated: 2017-03-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 152 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2015-07-31

Brief Summary

This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+ posttransplant lymphoproliferative disorders (PTLD). However, responders to rituximab achieving a CR after the first 4 applications of rituximab will go on with rituximab monotherapy and will not receive chemotherapy.

Detailed Description

The rationale for performing the present study is to combine two highly active treatment modalities in first line therapy of solid organ recipients with B-cell PTLD. The monoclonal antibody CD20 represents an effective therapeutic approach in the treatment of PTLD. Unfortunately this effect seems to be of limited duration in some patients, who benefited from monotherapy with rituximab. The advantage of this therapeutic approach in PTLD is due to the low incidence of third to fourth degree adverse events. At diagnosis of PTLD a relevant proportion of these patients is not suitable for first line cytotoxic chemotherapy due to widespread disease, organ dysfunction or reduced performance state. Insufficiencies of kidney or bone marrow function are frequent in organ recipients due the toxic side effects of the immunosuppressive drugs. After pre-phase treatment with the monoclonal antibody rituximab the CHOP chemotherapy is suggested to be less toxic due to the lower tumor burden. Thereby treatment related severe or even lethal toxicities, frequently reported in patients with PTLD who underwent cytotoxic chemotherapy, may be prevented. Furthermore the total number of cytotoxic cycles of CHOP-therapy is reduced from 6 for 8 to 4 cycles and thus may result in an additional reduction of toxicity in the single patient. Because immunochemotherapy (R-CHOP) is clearly superior to CHOP with respect to progression free survival and relapse rates in patients with classical NHL and rituximab is very unlikely to add any further toxicity to CHOP the majority of patients will go on with four courses of R-CHOP. However, patients with a complete remission after 4 courses of single agent rituximab may have a very favourable risk profile and therefore will go on with rituximab single agent instead of R-CHOP.

Conditions

PTLD; Posttransplant Lymphoproliferative Disorder

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.

Group Type: EXPERIMENTAL

rituximab monotherapy

Intervention Type: DRUG

375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).

B

All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.

Group Type: EXPERIMENTAL

sequential R-CHOP

Intervention Type: DRUG

375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.

In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.

Interventions

rituximab monotherapy

375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).

Intervention Type: DRUG

sequential R-CHOP

375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.

In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• PTLD with or without EBV association, confirmed after biopsy or resection of tumor
• Measurable disease of > 2 cm in diameter and/or bone marrow involvement
• Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or other or a combination of the organ transplantations mentioned
• Karnofsky scale >50% or ECOG ≤ 3
• Reduction of immunosuppression with or without antiviral therapy
• A complete surgical extirpation of tumor was not performed
• A radiation therapy was not performed
• Effective contraception for women in childbearing age
• Patient's written informed consent and written consent for data collection
• Patients are > 18 years (or ≥ 15 years with parental agreement )

Exclusion Criteria

• Life expectancy less than 6 weeks
• Karnofsky-scale <50% or ECOG ≥ 3
• Treatment with rituximab before
• Known allergic reactions against foreign proteins
• Concomitant diseases, which exclude the administration of therapy as outlined by the study protocol
• non-compensated heart failure
• Dilatative cardiomyopathy
• Myocardial infarction during the last 6 months
• Severe non-compensated hypertension
• Severe non-compensated diabetes mellitus
• Renal insufficiency (creatinine more than 3-fold of the upper normal value), not related to lymphoma
• Hepatic insufficiency with transaminase values greater than 3-fold of the normal values and/or bilirubin levels >3.0 mg/dl, not related to lymphoma
• Clinical signs of cerebral dysfunction
• Women during the lactation period, pregnant or of childbearing potential not using a reliable contraceptive method
• Involvement of the central nervous system by the disease
• Severe psychiatric disease
• Known to be HIV positive
• Missing written informed consent of the patient

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Charite University, Berlin, Germany

OTHER

Sponsor Role: lead

Responsible Party

Ralf Trappe

Head German PTLD Study Group

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hanno Riess, MD

Role: PRINCIPAL_INVESTIGATOR

Charité, Campus Virchow-Klinikum Berlin, Germany

Ralf U Trappe, MD

Role: STUDY_CHAIR

Charité, Campus Virchow-Klinkum, Berlin, Germany

Locations

Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, Qld 4102

Brisbane, , Australia

Catholic University of Leuven, Department of Hematology

Leuven, , Belgium

Hôpital Pitié-Salpétrière, Department of Hematology, 47-83 Boulevard de l'Hopital

Paris, , France

Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Hematology and Oncology, Augustenburger Platz 1

Berlin, , Germany

Div. Universitaria Ematologia e Terapie Cellulari, University of Torino

Torino, , Italy

Zakład Propedeutyki Onkologii, Gdańskiego Uniwersytetu Medycznego

Gdynia, , Poland

Sahlgrens hospital, Department of Hematology

Gothenburg, , Sweden

Countries

Australia; Belgium; France; Germany; Italy; Poland; Sweden

References

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Duhrsen U, Reinke P, Verhoef G, Subklewe M, Huttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19.

Reference Type: RESULT

PMID: 27992268 (View on PubMed)

Other Identifiers

EudraCT 2005-000743-29

Identifier Type: -

Identifier Source: secondary_id

PTLD-1, 3rd. amendment

Identifier Type: -

Identifier Source: org_study_id